Final guidance for treating neuroendocrine tumours (NETs)

Guidance issued by NICE (England) for treating neuroendocrine tumours (NETs) Final guidance recommending everolimus (Infinitor, Novartis) and sunitinib (Sutent, Pfizer) to treat neuroendocrine tumours (NETs). The drugs are recommended as an option for pancreatic NETs that cannot be operated on and have progressed. Everolimus is also recommended as an option for those with NETs of…

Read More

uk: Two eye treatments for serious diabetic eye conditions

Two eye treatments for serious diabetic eye condition – final draft guidance NICE recommended aflibercept solution for injection (Eylea, Bayer Pharma), and dexamethasone intravitreal(i) implant (Ozurdex, Allergan) as possible treatment options for some people with diabetic macular oedema, in two separate pieces of final draft guidance published (2 June). This oedema is a common complication…

Read More

8th European Public Health Conference

Event 8th European Public Health Conference Wed., 14 – 17th Oct 2015, MiCo Milano Congressi, Milan, Italy Organized by the European Public Health Conference Foundation, the European Public Health Association (EUPHA) and the Italian Society of Hygiene, Preventive Medicine and Public Health (SItI). The event will contribute to improving public health in Europe by offering…

Read More

uk: Recommendation for knee cartilage treatment

Research recommendation for knee cartilage treatment NICE has opened a public consultation on draft guidance on a procedure which aims to repair defects in knee cartilage. This procedure is autologous chondrocyte implantation (ACI) and recommends that this is used only in research, as more evidence is needed on how it works in longer term and…

Read More

UK: Treatment guides for treating kidney and prostate cancer

Final guidance on use of axitinib for treating kidney cancer and sipuleucel-T for prostate cancer. Guidance issued to the NHS today, recommends that the drug axitinib, known as Inlyta by Pfizer, should be available as a second line treatment for kidney cancer. A separate new guide did not recommended sipuleucel-T, known as Provenge, for treating…

Read More

UK: Dexamethasone treatment for diabetic eye condition

Dexamethasone treatment of common diabetic eye condition. NICE is recommending dexamethasone (Ozurdex, Allergan) intravitreal(1) implant, for the treatment of diabetic macular oedema (DMO) in preliminary recommendations published 20/02/ 2015. The draft guidance recommends dexamethasone as a treatment option in people only where:  the implant is to be used in an eye with an intraocular (pseudophakic)(2)…

Read More